Investment management company Harbor Funds revealed in its Q2 2026 investor letter that it has added biotechnology firm Regeneron Pharmaceuticals (NASDAQ:REGN) to its holdings. The fund highlighted Regeneron's strong performance in cash flow and forecasted earnings, robust price momentum over the past 12 months, improving operating margins, and sales growth as key reasons for the purchase. Regeneron Pharmaceuticals closed at $827.72 per share on September 4, 2026, with a market capitalization of $85.21 billion, having gained 2.43% over the past month and 48.22% over the past 52 weeks.